Cantor Fitzgerald Reaffirms "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Cantor Fitzgerald reiterated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a report released on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock.

TSHA has been the subject of a number of other reports. JMP Securities reissued a market outperform rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Chardan Capital raised their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a buy rating in a report on Thursday, March 21st. Canaccord Genuity Group reaffirmed a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Piper Sandler started coverage on shares of Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of Buy and an average price target of $6.88.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock traded down $0.04 on Thursday, reaching $2.41. 1,968,806 shares of the company traded hands, compared to its average volume of 2,669,072. Taysha Gene Therapies has a 52 week low of $0.50 and a 52 week high of $3.89. The company has a 50 day moving average of $2.53 and a 200 day moving average of $2.10. The firm has a market capitalization of $450.72 million, a PE ratio of -3.58 and a beta of 0.29. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $4.75 million. Equities analysts forecast that Taysha Gene Therapies will post -0.39 earnings per share for the current year.

Institutional Trading of Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the company. Capital Investment Advisors LLC purchased a new stake in Taysha Gene Therapies in the 3rd quarter worth approximately $32,000. AQR Capital Management LLC purchased a new stake in Taysha Gene Therapies in the 2nd quarter worth approximately $38,000. Howard Capital Management Inc. purchased a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $25,000. Maven Securities LTD purchased a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $34,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $28,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.